VIEW POINT

Their core work

VIEW POINT is a French SME that develops automated, real-time water toxicity monitoring systems. Their flagship product, ToxMate, provides continuous on-line monitoring of wastewater and water quality, enabling utilities and industrial operators to detect contamination events as they happen. The company progressed from a Phase 1 feasibility study to a full Phase 2 commercialization project under the SME Instrument, indicating a product moving toward market readiness.

What they specialise in

How they've shifted over time

VIEW POINT's early H2020 involvement (2015) was as a third party in MiND, a training network for neurodevelopmental disorders — a domain quite distant from their later focus. From 2018 onward, they pivoted entirely to water toxicity monitoring, first validating the ToxMate concept through an SME-1 feasibility study and then scaling it with a substantial SME-2 grant of over EUR 1.2M. This trajectory shows a company that found its core product-market fit in environmental monitoring and doubled down on it.

VIEW POINT is moving from R&D into commercialization of their ToxMate water monitoring system, making them a strong candidate for demonstration and deployment partnerships in the water sector.

How they like to work

VIEW POINT predominantly leads its own projects — two of three H2020 participations were as coordinator, both under the SME Instrument which funds single-company innovation. Their one partner role was as a third party, not a full consortium member. This profile suggests a product-driven company that prefers to own its development roadmap rather than embed in large multi-partner consortia.

With 21 unique partners across 9 countries, VIEW POINT has a moderately broad European network, though most of this network likely comes through the MiND training network rather than their core water monitoring work. Their SME Instrument projects were single-beneficiary, so direct collaboration depth may be limited.

What sets them apart

VIEW POINT is one of few SMEs to have completed the full SME Instrument pathway (Phase 1 to Phase 2) for water toxicity monitoring, signalling both technical maturity and EU-validated market potential. Their ToxMate system addresses a growing regulatory need for continuous water quality surveillance, positioning them at the intersection of environmental compliance and industrial IoT. For consortium builders in the water sector, they bring a near-market product rather than early-stage research.

Highlights from their portfolio

• ToxMate
  Received EUR 1.23M in SME-2 funding for commercialization of their water toxicity monitoring system — their largest and most strategically important project.
• MiND
  Unusual cross-domain involvement in a neurodevelopmental training network, suggesting the company has broader technical roots than its current water focus implies.